Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705280 | 1.00 | PGD (0.35) | PGDCA1CA2CA7CYP2D6 | |
| SCHEMBL7181932 | 1.00 | PGD (0.35) | PGDCA1CA2CA7CYP2D6 | |
| SCHEMBL13007214 | 0.84 | TDP1 (0.44) | CA1CA2CA7CYP2D6MEN1 | |
| SCHEMBL7277806 | 0.84 | CYP2D6 (0.32) | PGDCA1CA2CA7CYP2D6 | |
| SCHEMBL10703266 | 0.83 | CYP2D6 (0.46) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL12526882 | 0.83 | CYP2D6 (0.46) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL28052779 | 0.80 | CYP2D6 (0.32) | CA1CA2CA7CYP2D6MEN1 | |
| SCHEMBL28052674 | 0.80 | CYP2D6 (0.32) | CA1CA2CA7CYP2D6MEN1 | |
| SCHEMBL27891039 | 0.80 | CYP2D6 (0.32) | CA1CA2CA7CYP2D6MEN1 | |
| SCHEMBL29943608 | 0.80 | TDP1 (0.44) | PGDCA1CA2CA7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276244-B | Preparation method of carboxylic acid compound and metal salt derivative thereof | 苏州汉酶生物技术有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-118931983-A | Sakuba starter intermediate and preparation method thereof | 苏州弗莱明生物技术有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114276244-B | Preparation method of carboxylic acid compound and metal salt derivative thereof | 苏州汉酶生物技术有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-114276244-A | Preparation method of carboxylic acid compound and metal salt derivative thereof | 苏州汉酶生物技术有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-8008250-B2 | 1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-9,10-dimethyl-2-oxa-9,12-diaza-bicyclo[13.3.1]nonadeca-1(19),15,17-triene-8,11-dione; secretase inhibitor; neurological, vascular disorders, beta-amyloid generation/aggregation; Alzheimer's disease, Down's Syndrome, cognitive impairment, amyloid neuropathies | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
| CN-101090894-A | Macrocyclic compounds and compositions useful as BACE inhibitors | NOVARTIS AG (CH) | 2007-12-19 | — | — | CN | disclosed |
| CN-101087820-A | Polymer composition, plastic optical fiber, plastic optical cable, and method for producing plastic optical fiber | MITSUBISHI RAYON CO (JP) | 2007-12-12 | — | — | CN | disclosed |
| EP-1838680-A2 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006074940-A2 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | BACE1, BACE2, APP | PGD 3698/4885CA1 44/4885CA2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.